Literature DB >> 22320225

Structural and functional characterization of the product of disease-related factor H gene conversion.

Andrew P Herbert1, David Kavanagh, Conny Johansson, Hugh P Morgan, Bärbel S Blaum, Jonathan P Hannan, Paul N Barlow, Dušan Uhrín.   

Abstract

Numerous complement factor H (FH) mutations predispose patients to atypical hemolytic uremic syndrome (aHUS) and other disorders arising from inadequately regulated complement activation. No unifying structural or mechanistic consequences have been ascribed to these mutants beyond impaired self-cell protection. The S1191L and V1197A mutations toward the C-terminus of FH, which occur in patients singly or together, arose from gene conversion between CFH encoding FH and CFHR1 encoding FH-related 1. We show that neither single nor double mutations structurally perturbed recombinant proteins consisting of the FH C-terminal modules, 19 and 20 (FH19-20), although all three FH19-20 mutants were poor, compared to wild-type FH19-20, at promoting hemolysis of C3b-coated erythrocytes through competition with full-length FH. Indeed, our new crystal structure of the S1191L mutant of FH19-20 complexed with an activation-specific complement fragment, C3d, was nearly identical to that of the wild-type FH19-20:C3d complex, consistent with mutants binding to C3b with wild-type-like affinity. The S1191L mutation enhanced thermal stability of module 20, whereas the V1197A mutation dramatically decreased it. Thus, although mutant proteins were folded at 37 °C, they differ in conformational rigidity. Neither single substitutions nor double substitutions increased measurably the extent of FH19-20 self-association, nor did these mutations significantly affect the affinity of FH19-20 for three glycosaminoglycans, despite critical roles of module 20 in recognizing polyanionic self-surface markers. Unexpectedly, FH19-20 mutants containing Leu1191 self-associated on a heparin-coated surface to a higher degree than on surfaces coated with dermatan or chondroitin sulfates. Thus, potentially disease-related functional distinctions between mutants, and between FH and FH-related 1, may manifest in the presence of specific glycosaminoglycans.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22320225     DOI: 10.1021/bi201689j

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  13 in total

1.  A Therapeutic Antibody for Cancer, Derived from Single Human B Cells.

Authors:  Ryan T Bushey; M Anthony Moody; Nathan L Nicely; Barton F Haynes; S Munir Alam; Stephen T Keir; Rex C Bentley; Kingshuk Roy Choudhury; Elizabeth B Gottlin; Michael J Campa; Hua-Xin Liao; Edward F Patz
Journal:  Cell Rep       Date:  2016-05-05       Impact factor: 9.423

2.  Structural basis for sialic acid-mediated self-recognition by complement factor H.

Authors:  Bärbel S Blaum; Jonathan P Hannan; Andrew P Herbert; David Kavanagh; Dušan Uhrín; Thilo Stehle
Journal:  Nat Chem Biol       Date:  2014-11-24       Impact factor: 15.040

3.  HUS with mutations in CFH and STEC infection treated with eculizumab in a 4-year-old girl.

Authors:  Carla Galvez; Paola Krall; Alejandro Rojas; Jun Oh; Francisco Cano
Journal:  Pediatr Nephrol       Date:  2022-08-15       Impact factor: 3.651

4.  Liver transplantation for aHUS: still needed in the eculizumab era?

Authors:  Rosanna Coppo; Roberto Bonaudo; R Licia Peruzzi; Alessandro Amore; Andrea Brunati; Renato Romagnoli; Mauro Salizzoni; Miriam Galbusera; Eliana Gotti; Erica Daina; Marina Noris; Giuseppe Remuzzi
Journal:  Pediatr Nephrol       Date:  2015-11-24       Impact factor: 3.714

5.  Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN.

Authors:  Edwin K S Wong; Holly E Anderson; Andrew P Herbert; Rachel C Challis; Paul Brown; Geisilaine S Reis; James O Tellez; Lisa Strain; Nicholas Fluck; Ann Humphrey; Alison Macleod; Anna Richards; Daniel Ahlert; Mauro Santibanez-Koref; Paul N Barlow; Kevin J Marchbank; Claire L Harris; Timothy H J Goodship; David Kavanagh
Journal:  J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 10.121

6.  The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease.

Authors:  Arnab Bhattacharjee; Stefanie Reuter; Eszter Trojnár; Robert Kolodziejczyk; Harald Seeberger; Satu Hyvärinen; Barbara Uzonyi; Ágnes Szilágyi; Zoltán Prohászka; Adrian Goldman; Mihály Józsi; T Sakari Jokiranta
Journal:  J Biol Chem       Date:  2015-02-06       Impact factor: 5.157

Review 7.  Properdin: a tightly regulated critical inflammatory modulator.

Authors:  Adam Z Blatt; Sabina Pathan; Viviana P Ferreira
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

8.  Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions.

Authors:  Simon J Clark; Liam A Ridge; Andrew P Herbert; Svetlana Hakobyan; Barbara Mulloy; Rachel Lennon; Reinhard Würzner; B Paul Morgan; Dusan Uhrín; Paul N Bishop; Anthony J Day
Journal:  J Immunol       Date:  2013-01-30       Impact factor: 5.422

Review 9.  Atypical hemolytic uremic syndrome.

Authors:  David Kavanagh; Tim H Goodship; Anna Richards
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

10.  An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy.

Authors:  Yi Yang; Harriet Denton; Owen R Davies; Kate Smith-Jackson; Heather Kerr; Andrew P Herbert; Paul N Barlow; Matthew C Pickering; Kevin J Marchbank
Journal:  J Am Soc Nephrol       Date:  2018-03-27       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.